APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drug Repurposing

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drug Repurposing Market Outlook and Growth Opportunities 2026

22 December 2025190 pages

Choose your research edition.

Industry ResearchDrug Repurposing Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug Repurposing Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Drug Repurposing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug Repurposing Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Drug Repurposing Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Drug Repurposing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drug Repurposing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drug Repurposing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drug Repurposing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drug Repurposing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drug Repurposing market include Novartis, Pfizer, AbbVie, NuMedii, Biovista, Astellas Pharma and Allergan, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Drug Repurposing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drug Repurposing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drug Repurposing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drug Repurposing market.

Drug Repurposing Segment by Company

Novartis

Pfizer

AbbVie

NuMedii

Biovista

Astellas Pharma

Allergan

Drug Repurposing Segment by Type

Neurodegenerative Diseases

CNS Diseases

Oncology

Others

Drug Repurposing Segment by Application

Hospitals

Ambulatory Surgical Centers

Others

Drug Repurposing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drug Repurposing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drug Repurposing key companies, revenue, market share, and recent developments.

3. To split the Drug Repurposing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drug Repurposing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drug Repurposing significant trends, drivers, influence factors in global and regions.

6. To analyze Drug Repurposing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Repurposing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug Repurposing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Repurposing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drug Repurposing industry.

Chapter 3: Detailed analysis of Drug Repurposing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drug Repurposing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drug Repurposing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drug Repurposing Industry Trends Table 2. Drug Repurposing Industry Drivers Table 3. Drug Repurposing Industry Opportunities and Challenges Table 4. Drug Repurposing Industry Restraints Table 5. Global Drug Repurposing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drug Repurposing Revenue Share by Company (2021-2026) Table 7. Global Drug Repurposing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drug Repurposing Key Company Manufacturing Base & Headquarters Table 9. Global Drug Repurposing Company, Product Type & Application Table 10. Global Drug Repurposing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drug Repurposing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Neurodegenerative Diseases Table 15. Significant Companies of CNS Diseases Table 16. Significant Companies of Oncology Table 17. Significant Companies of Others Table 18. Global Drug Repurposing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Drug Repurposing Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Drug Repurposing Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Drug Repurposing Sales Value Share by Type (2021-2026) Table 22. Global Drug Repurposing Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospitals Table 24. Significant Companies of Ambulatory Surgical Centers Table 25. Significant Companies of Others Table 26. Global Drug Repurposing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Drug Repurposing Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Drug Repurposing Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Drug Repurposing Sales Value Share by Application (2021-2026) Table 30. Global Drug Repurposing Sales Value Share by Application (2027-2032) Table 31. Global Drug Repurposing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Drug Repurposing Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Drug Repurposing Sales Value Share by Region (2021-2026) Table 34. Global Drug Repurposing Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Drug Repurposing Sales Value Share by Region (2027-2032) Table 36. Global Drug Repurposing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Drug Repurposing Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Drug Repurposing Sales Value Market Share by Country (2021-2026) Table 39. Global Drug Repurposing Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Drug Repurposing Sales Value Market Share by Country (2027-2032) Table 41. Novartis Company Information Table 42. Novartis Business Overview Table 43. Novartis Drug Repurposing Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Novartis Drug Repurposing Product Portfolio Table 45. Novartis Recent Development Table 46. Pfizer Company Information Table 47. Pfizer Business Overview Table 48. Pfizer Drug Repurposing Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Pfizer Drug Repurposing Product Portfolio Table 50. Pfizer Recent Development Table 51. AbbVie Company Information Table 52. AbbVie Business Overview Table 53. AbbVie Drug Repurposing Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. AbbVie Drug Repurposing Product Portfolio Table 55. AbbVie Recent Development Table 56. NuMedii Company Information Table 57. NuMedii Business Overview Table 58. NuMedii Drug Repurposing Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. NuMedii Drug Repurposing Product Portfolio Table 60. NuMedii Recent Development Table 61. Biovista Company Information Table 62. Biovista Business Overview Table 63. Biovista Drug Repurposing Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Biovista Drug Repurposing Product Portfolio Table 65. Biovista Recent Development Table 66. Astellas Pharma Company Information Table 67. Astellas Pharma Business Overview Table 68. Astellas Pharma Drug Repurposing Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Astellas Pharma Drug Repurposing Product Portfolio Table 70. Astellas Pharma Recent Development Table 71. Allergan Company Information Table 72. Allergan Business Overview Table 73. Allergan Drug Repurposing Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Allergan Drug Repurposing Product Portfolio Table 75. Allergan Recent Development Table 76. Research Programs/Design for This Report Table 77. Authors List of This Report Table 78. Secondary Sources Table 79. Primary Sources List of Figures Figure 1. Drug Repurposing Product Image Figure 2. Global Drug Repurposing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug Repurposing Market Size (2021-2032) & (US$ Million) Figure 4. Global Drug Repurposing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Neurodegenerative Diseases Image Figure 8. CNS Diseases Image Figure 9. Oncology Image Figure 10. Others Image Figure 11. Global Drug Repurposing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Drug Repurposing Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Drug Repurposing Sales Value Share by Type (2021-2032) Figure 14. Hospitals Image Figure 15. Ambulatory Surgical Centers Image Figure 16. Others Image Figure 17. Global Drug Repurposing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Drug Repurposing Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Drug Repurposing Sales Value Share by Application (2021-2032) Figure 20. Global Drug Repurposing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Drug Repurposing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Drug Repurposing Sales Value (2021-2032) & (US$ Million) Figure 23. North America Drug Repurposing Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Drug Repurposing Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Drug Repurposing Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Drug Repurposing Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Drug Repurposing Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Drug Repurposing Sales Value (2021-2032) & (US$ Million) Figure 29. South America Drug Repurposing Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Drug Repurposing Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Drug Repurposing Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Drug Repurposing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Drug Repurposing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Drug Repurposing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Neurodegenerative Diseases
  • CNS Diseases
  • Oncology
  • Others
Applications
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
Companies covered
  • Novartis
  • Pfizer
  • AbbVie
  • NuMedii
  • Biovista
  • Astellas Pharma
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drug Repurposing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drug Repurposing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drug Repurposing Market Dynamics
  1. 2.1 Drug Repurposing Industry Trends
  2. 2.2 Drug Repurposing Industry Drivers
  3. 2.3 Drug Repurposing Industry Opportunities and Challenges
  4. 2.4 Drug Repurposing Industry Restraints
3 Drug Repurposing Market by Company
  1. 3.1 Global Drug Repurposing Company Revenue Ranking in 2025
  2. 3.2 Global Drug Repurposing Revenue by Company (2021-2026)
  3. 3.3 Global Drug Repurposing Company Ranking (2024-2026)
  4. 3.4 Global Drug Repurposing Company Manufacturing Base and Headquarters
  5. 3.5 Global Drug Repurposing Company Product Type and Application
  6. 3.6 Global Drug Repurposing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drug Repurposing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drug Repurposing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drug Repurposing Market by Type
  1. 4.1 Drug Repurposing Type Introduction
  2. 4.1.1 Neurodegenerative Diseases
  3. 4.1.2 CNS Diseases
  4. 4.1.3 Oncology
  5. 4.1.4 Others
  6. 4.2 Global Drug Repurposing Sales Value by Type
  7. 4.2.1 Global Drug Repurposing Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Drug Repurposing Sales Value by Type (2021-2032)
  9. 4.2.3 Global Drug Repurposing Sales Value Share by Type (2021-2032)
5 Drug Repurposing Market by Application
  1. 5.1 Drug Repurposing Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Ambulatory Surgical Centers
  4. 5.1.3 Others
  5. 5.2 Global Drug Repurposing Sales Value by Application
  6. 5.2.1 Global Drug Repurposing Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drug Repurposing Sales Value by Application (2021-2032)
  8. 5.2.3 Global Drug Repurposing Sales Value Share by Application (2021-2032)
6 Drug Repurposing Regional Value Analysis
  1. 6.1 Global Drug Repurposing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drug Repurposing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drug Repurposing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drug Repurposing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drug Repurposing Sales Value (2021-2032)
  7. 6.3.2 North America Drug Repurposing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drug Repurposing Sales Value (2021-2032)
  10. 6.4.2 Europe Drug Repurposing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drug Repurposing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drug Repurposing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drug Repurposing Sales Value (2021-2032)
  16. 6.6.2 South America Drug Repurposing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drug Repurposing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drug Repurposing Sales Value Share by Country, 2025 VS 2032
7 Drug Repurposing Country-level Value Analysis
  1. 7.1 Global Drug Repurposing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drug Repurposing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drug Repurposing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drug Repurposing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drug Repurposing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drug Repurposing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drug Repurposing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drug Repurposing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drug Repurposing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drug Repurposing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drug Repurposing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drug Repurposing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drug Repurposing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drug Repurposing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drug Repurposing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drug Repurposing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drug Repurposing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drug Repurposing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drug Repurposing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drug Repurposing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drug Repurposing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drug Repurposing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drug Repurposing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drug Repurposing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drug Repurposing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drug Repurposing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drug Repurposing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drug Repurposing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drug Repurposing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drug Repurposing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drug Repurposing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drug Repurposing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drug Repurposing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drug Repurposing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drug Repurposing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Drug Repurposing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Drug Repurposing Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Drug Repurposing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Drug Repurposing Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 AbbVie
  14. 8.3.1 AbbVie Company Information
  15. 8.3.2 AbbVie Business Overview
  16. 8.3.3 AbbVie Drug Repurposing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AbbVie Drug Repurposing Product Portfolio
  18. 8.3.5 AbbVie Recent Developments
  19. 8.4 NuMedii
  20. 8.4.1 NuMedii Company Information
  21. 8.4.2 NuMedii Business Overview
  22. 8.4.3 NuMedii Drug Repurposing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 NuMedii Drug Repurposing Product Portfolio
  24. 8.4.5 NuMedii Recent Developments
  25. 8.5 Biovista
  26. 8.5.1 Biovista Company Information
  27. 8.5.2 Biovista Business Overview
  28. 8.5.3 Biovista Drug Repurposing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Biovista Drug Repurposing Product Portfolio
  30. 8.5.5 Biovista Recent Developments
  31. 8.6 Astellas Pharma
  32. 8.6.1 Astellas Pharma Company Information
  33. 8.6.2 Astellas Pharma Business Overview
  34. 8.6.3 Astellas Pharma Drug Repurposing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Astellas Pharma Drug Repurposing Product Portfolio
  36. 8.6.5 Astellas Pharma Recent Developments
  37. 8.7 Allergan
  38. 8.7.1 Allergan Company Information
  39. 8.7.2 Allergan Business Overview
  40. 8.7.3 Allergan Drug Repurposing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Allergan Drug Repurposing Product Portfolio
  42. 8.7.5 Allergan Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst